CRISPR, crispr genome editing system - Part 4

Jennifer Doudna Answers Questions about CRISPR

JENNIFER DOUDNA SPEAKS AT HER 13 FEBRUARY PLENARY SESSION AT THE 2016 AAAS ANNUAL MEETING. | BOSTON ATLANTIC PHOTOGRAPHY Last year, the genome-editing method CRISPR came to power as a technology poised to change everything from how we fight disease to whether we might finally be able to rid the world of the mosquito. The journal Science named CRISPR its Breakthrough of the Year, and Time magazine named one of its discoverers, University of California, Berkeley’s Jennifer Doudna, as one of the 100 most influential people in the world. In her 13 February plenary talk at the 2016 AAAS Annual Meeting, Doudna took her audience through the technical breakthroughs that turned her “curiosity-driven science project” on how bacteria build immunity against viruses...
Read More..

Cocrystal Pharma Announces In-Licensing of CRISPR Cas Technologies for Hepatitis B Virus and Human Papilloma Virus

ATLANTA, GA 02/10/16 Cocrystal Pharma, Inc. (OTCQB: COCP), a company focused on developing novel antiviral therapeutics for human diseases, announced today it has signed an agreement with Duke University and Emory University to license various patents and know-how to use CRISPR/Cas9 technologies for developing a possible cure for hepatitis B virus (HBV) and human papilloma virus (HPV). “We’re pleased to bring the CRISPR/Cas DNA editing technology developed in our laboratories into the clinic,” said Bryan R. Cullen, Ph.D., the James B. Duke Professor, Department of Molecular Genetics and Microbiology at Duke University School of Medicine. “We look forward to adding Cocrystal to our team as they are committed to helping the development of potential new treatment options for chronic HBV and...
Read More..

The billion-dollar CRISPR patent battle: A case of big money shaping science

crispr money
The 21st century is still young, but it may already have its era-defining patent fight. The contestants are the University of California and the Broad Institute, a Harvard- and MIT-affiliated research foundation endowed by Los Angeles billionaire Eli Broad. At stake are the rights to a breakthrough gene-editing technology known as CRISPR — and more precisely, to billions of dollars in royalties and license fees likely to flow to whichever claimant prevails before the U.S. Patent and Trademark Office (and in the almost inevitable appeals in court). “This is a monumental event for patent attorneys, molecular biologists, the PTO, and the world,” patent expert Jacob Sherkow wrote recently on Stanford’s Law and Biosciences blog. CRISPR — an acronym for the...
Read More..

CRISPR may be used for oil production through the yeast with edited genome

RIVERSIDE, Calif. ( — A team led by a researcher at the University of California, Riverside has adapted the CRISPR-Cas9 gene editing system for use in a yeast strain that can produce useful lipids and polymers. The development will lead to new precursors for biofuels, specialty polymers, adhesives and fragrances. Published recently in the journalACS Synthetic Biology, the research involves the oleaginous (oil-producing) yeast Yarrowia lipolytica, which is known for converting sugars to lipids and hydrocarbons that are difficult to make synthetically. Until now, Y. lipolytica has been hard to manipulate at the genetic level, but the application of CRISPR-Cas9 will change that, allowing scientists to tap into its bio-manufacturing potential. Described in 2012, CRISPR-Cas9 is a groundbreaking technique that...
Read More..

British researchers starts to genetically modify human embryos

crispr human
Scientists investigating miscarriage will not be able to implant embryos or study them for more than two weeks, says HFEA Britain’s first genetically modified human embryos could be created within months, after scientists were granted permission by the fertility regulator to carry out the procedure. The Human Fertilisation and Embryology Authority (HFEA) regulator approved a licence application by Kathy Niakan, a stem cell scientist at the Francis Crick Institute in London, to perform so-called genome editing on human embryos. The decision permits Niakan to study the embryos for 14 days for research purposes only. It does not permit them to be implanted into women. Niakan’s research is aimed at finding the genes at play in the early days of human...
Read More..

CRISPR Used To Repair Blindness-Causing Gene Defect

Hailed as a breakthrough with the potential to correct genetic mutations and cure life-threatening diseases, the gene editing platform CRISPR/Cas9 may also be able to reverse an inherited condition that causes blindness. Scientists at the Columbia University Medical Center and University of Iowa used CRISPR to repair a genetic mutation responsible for retinitis pigmentosa in induced pluripotent stem cells derived from a patient with the disease. Retinitis pigmentosa is a genetic eye condition that causes the retina to deteriorate, leading to a slow loss of vision and resulting in blindness in at least 1.5 million cases worldwide. There is no cure for retinitis pigmentosa, and the only treatment is vitamin A, which may help slow down the progression of vision loss in...
Read More..

New Gene Editing Technology Promises Most Monumental Advance of Humankind Into the Future

By Dr. Mercola In his 1932 sci-fi novel “Brave New World,” Aldous Huxley explored what life might be like in AD 2540 — a world in which children are born in government owned baby hatcheries. In his world, human freedom is virtually non-existent, as each individual is genetically engineered and psychologically conditioned to fulfill a specific role within one of the five societal classes. Over 500 years before his prediction, we’re already seeing the germination of some of his projections. The technical development that is taking medicine by storm is CRISPR (clustered regularly interspaced short palindromic repeat) — a gene editing tool that has the most profound potential to change the health world as we know it that I have...
Read More..

Editas Aims For $100M CRISPR IPO

crispr cas investment
Editas Medicine is pushing ahead with plans to go public. An IPO for the Cambridge, MA-based company would make it the first among the handful of biotechs that are betting on the groundbreaking CRISPR-Cas9 gene editing system to develop human therapeutics. In a regulatory filing posted today, Editas said it would aim to sell 5.9 million shares in the $16 to $18 range. The midpoint of that range would add up to a $100 million IPO and leave the company, for the moment, with a market value just north of $600 million. If all goes well, bankers could sell extra shares and bump the deal total to $122 million. Though the blizzard that just buried the East Coast largely spared...
Read More..

U.S. researchers improve CRISPR gene editing technique

SAN FRANCISCO, Jan. 20 (Xinhua) — Researchers at University of California, Berkeley, have improved CRISPR-Cas9 technology and achieved a success rate of 60 percent when replacing a short stretch of DNA with another. The advance in CRISPR, short for clustered regularly interspaced short palindromic repeats, using the Cas9 protein is useful when trying to repair genetic mutations that cause hereditary diseases, such as sickle cell disease or severe combined immune deficiency. The study at the university on the U.S. west coast about gene editing, a major biotech research area in recent years, is published in the Jan. 21 issue of the journal Nature Biotechnology. “The exciting thing about CRISPR-Cas9 is the promise of fixing genes in place in our genome,...
Read More..

Crispr goes commercial: Genetic goldrush

crispr cas investment
Within just three years since the discovery of its gene-editing potential, the new technique Crispr has become the hottest, and most controversial, development in genomics research. And now it’s more than just a science – it’s big business too. First discovered in bacteria, Crispr (clustered regularly interspaced short palindromic repeats) is a genome-editing tool that can target specific genes in any organism based on RNA–DNA base pairing and then precisely cut the gene through the activities of the enzyme known as Crispr-associated protein 9 or Cas9. The technology can delete, repair or replace genes, and is faster, easier, cheaper and – in principle – more precise than other gene-editing techniques. With potential benefits across human health, agriculture and industrial biotechnology,...
Read More..